A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge

American Journal of Gastroenterology

Volumn 107, Issue 10, 2012, Pages 1554-1562

  Leffler, Daniel A ^a   Kelly, C P ^a   Abdallah, H Z ^a,f   Colatrella, A M ^b   Harris, L A ^c   Leon, F ^d,g   Arterburn, L A ^d,h   Paterson, B M ^d,i   Lan, Z H ^d,j   Murray, J A ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Pittsburgh Gastroenterology Associates   (United States)

^c MAYO CLINIC   (United States)

^d Alba Therapeutics Corporation   (United States)

^e MAYO CLINIC   (United States)

^f Bay Area Houston Gastroenterology   (United States)

^g Centocor Research and Development   (United States)

^h INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUTEN; LACTULOSE; LARAZOTIDE; MANNITOL; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUTEN FREE DIET; HEADACHE; HUMAN; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION; URINARY TRACT INFECTION;

ACUTE DISEASE; ADULT; CELIAC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; GLUTENS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RECURRENCE; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; TIGHT JUNCTIONS;

EID: 84867101199     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.211     Document Type: Article

References (47)

1. Fasano A, Berti I, Gerarduzzi T et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163: 286-92.
2. Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357: 1731-43.
3. Fasano A. European and North American populations should be screened for coeliac disease. Gut 2003; 52: 168-9.
4. Catassi C, Fabiani E, Iacono G et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007; 85: 160-6.
5. Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 2005; 128: S74-8.
6. Murray JA, Van Dyke C, Plevak MF et al. Trends in the identifi cation and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol 2003; 1: 19-27.
7. Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2002; 346: 180-8.
8. Rubio-Tapia A, Murray JA. Celiac disease. Curr Opin Gastroenterol 2010; 26: 116-22.
9. Ludvigsson JF, Green PH. Clinical management of coeliac disease. J Int Med 2011; 269: 560-71.
10. Green PH, Fleischauer AT, Bhagat G et al. Risk of malignancy in patients with celiac disease. Am J Med 2003; 115: 191-5.
11. Jabri B, Kasarda DD, Green PH. Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev 2005; 206: 219-31.
12. Leffl er DA, Edwards-George J, Dennis M et al. Factors that infl uence adherenceto a gluten-free diet in adults with celiac disease. Dig Dis Sci 2008; 53: 1573-81.
13. Gibert A, Espadaler M, Angel Canela M et al. Consumption of gluten-free products: should thethreshold value for trace amounts of gluten be at 20, 100 or 200 p.p.m.? Eur J Gastroenterol Hepatol 2006; 18: 1187-95.
14. Mayer M, Greco L, Troncone R et al. Compliance of adolescents with coeliac disease with a gluten free diet. Gut 1991; 32: 881-5.
15. Collin P, Thorell L, Kaukinen K et al. The safethreshold for gluten contamination in gluten-free products. Can trace amounts be accepted in thetreatment of coeliac disease? Aliment Pharmacol Ther 2004; 19: 1277-83.
16. Midhagen G, Hallert C. High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol 2003; 98: 2023-6.
17. Ciacci C, Cirillo M, Cavallaro R et al. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion 2002; 66: 178-85.
18. Lee SK, Lo W, Memeo L et al. Duodenal histology in patients with celiac disease aft er treatment with a gluten-free diet. Gastrointest Endosc 2003; 57: 187-91.
19. Rubio-Tapia A, Rahim MW, See JA et al. Mucosal recovery and mortality in adults with celiac disease aft er treatment with a gluten-free diet. Am J Gastroenterol 2010; 105: 1412-20.
20. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137: 1912-33.
21. NIH. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. Gastroenterology 2005; 128: S1-9.
22. Zimmer KP, Poremba C, Weber P et al. Translocation of gliadin into HLA-DR antigen containing lysosomes in coeliac disease enterocytes. Gut 1995; 36: 703-9.
23. Matysiak-Budnik T, Candalh C, Dugave C et al. Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology 2003; 125: 696-707.
24. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via thetransferrin receptor in celiac disease. J Exp Med 2008; 205: 143-54.
25. Schumann M, Richter JF, Wedell I et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut 2008; 57: 747-54.
26. Koning F. Celiac disease: caught between a rock and a hard place. Gastroenterology 2005; 129: 1294-301.
27. Clemente MG, De Virgiliis S, Kang JS et al. Early eff ects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003; 52: 218-23.
28. Vorobjova T, Uibo O, Ojakivi I et al. Lower expression of tight junction protein 1 gene and increased FOXP3 expression in the small bowel mucosa in coeliac disease and associated type 1 diabetes mellitus. Inter Arch Allergy Immunol 2011; 156: 451-61.
29. Schumann M, Gunzel D, Buergel N et al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut 2012; 61: 220-8.
30. van Elburg RM, Uil JJ, Mulder CJ et al. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut 1993; 34: 354-7.
31. Wapenaar MC, Monsuur AJ, van Bodegraven AA et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut 2008; 57: 463-7.
32. van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for celiac disease identifi es risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39: 827-9.
33. Hrdlickova B, Westra HJ, Franke L et al. Celiac disease: moving from genetic associations to causal variants. Clin Genet 2011; 80: 203-313.
34. Gopalakrishnan S, Tripathi A, Tamiz AP et al. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 2012; 35: 95-101.
35. Gopalakrishnan S, Durai M, Kitchens K et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 2012; 35: 86-94.
36. Di Pierro M, Lu R, Uzzau S et al. Zonula occludens toxin structure-function analysis. Identifi cation of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem 2001; 276: 19160-5.
37. Paterson BM, Lammers KM, Arrieta MC et al. The safety, tolerance, pharmacokinetic and pharmacodynamic eff ects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007; 26: 757-66.
38. Meddings JB, Gibbons I. Discrimination of site-specifi c alterations in gastrointestinal permeability in the rat. Gastroenterology 1998; 114: 83-92.
39. Dimenas E, Carlsson G, Glise H et al. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8-13.
40. Dimenas E, Glise H, Hallerback B et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-52.
41. Revicki DA, Wood M, Wiklund I et al. Reliability and validity of the Gastrointestinal symptom rating scale in patients with gastroesophageal refl ux disease. Qual Life Res 1998; 7: 75-83.
42. Mustalahti K, Lohiniemi S, Collin P et al. Gluten-free diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract 2002; 5: 105-13.
43. Dupuy HJ. The psychological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CF, et al., (eds). Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq Publishing: New York, 1984 pp. 170-83.
44. Lohiniemi S, Maki M, Kaukinen K et al. Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets. Scand J Gastroenterol Suppl 2000; 35: 947-9.
45. Hallert C, Granno C, Grant C et al. Quality of life of adult coeliac patients treated for 10 years. Scand J Gastroenterol Suppl 1998; 33: 933-8.
46. Ukkola A, Maki M, Kurppa K et al. Diet improves perception of health and well-being in symptomatic, but not asymptomatic, patients with celiac disease. Clin Gastroenterol Hepatol 2011; 9: 118-23.
47. Hallert C, Svensson M, Tholstrup J et al. Clinical trial: B vitamins improve health in patients with coeliac disease living on a gluten-free diet. Aliment Pharmacol Ther 2009; 29: 811-6.